Skip to main content

Simon Gray Gregory

Margaret Harris and David Silverman Distinguished Professor
Neurosurgery, Neuro-Oncology
Duke Box 104775, Durham, NC 27701
300 N. Duke Street, Room 51-102, Duke Molecular Physiology Institute, Durham, NC 27701

Scholarly Works - Conferences


Abstract 1997: Integrative single-nuclei spatial transcriptomic profiling of primary and recurrent human glioblastoma reveals cell-specific EGFRvIII expression and ANXA1 signaling axis.

Conference Cancer Research · April 3, 2026 AbstractThe World Health Organization provides clear criteria for diagnosing IDH1-wildtype glioblastoma (GBM), relying on traditional approaches to define pathoetiological features, genomic mutations, cop ... Full text Cite

BIOM-72. INTEGRATIVE SINGLE-NUCLEI SPATIAL TRANSCRIPTOMIC PROFILING OF PRIMARY AND RECURRENT HUMAN IDH-WILDTYPE GLIOBLASTOMA REVEALS CELL-SPECIFIC EGFRVIII EXPRESSION AND ANXA1 SIGNALING AXIS

Conference Neuro-Oncology · November 11, 2025 AbstractThe World Health Organization provides clear criteria for diagnosing IDH1-wildtype glioblastoma (GBM), relying on traditional approaches to define pathoetiological features, genomic mutations, cop ... Full text Cite

BIOM-89. PI3K PATHWAY ALTERATIONS ARE DRIVERS OF PROGRESSION AND PREDICT WORSE OVERALL SURVIVAL IN NEWLY DIAGNOSED MOLECULARLY-DEFINED OLIGODENDROGLIOMA

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDIdentification of biomarkers for overall survival (OS) in oligodendroglioma has proven challenging due to 1) ... Full text Cite

EPCO-42. SINGLE-CELL MULTIOMIC ANALYSIS OF BRAIN METASTASES ACROSS MULTIPLE PRIMARY TUMOR TYPES

Conference Neuro-Oncology · November 11, 2024 AbstractBrain metastases are the most common form of intracranial tumor in adults, however the prognosis remains dismal due to lack of effective treatments and limited understanding of the underlying physiol ... Full text Cite

BIOM-30. NOVEL HISTOLOGIC AND MOLECULAR BIOMARKERS FOR OLIGODENDROGLIOMA

Conference Neuro-Oncology · November 11, 2024 AbstractOligodendrogliomas are progressive, infiltrative gliomas. While new molecular criteria were introduced in 2016 for diagnosing oligodendroglioma, the grading criteria remains largely unchanged. We eva ... Full text Cite

Prognostic impact of CDKN2A deletion in oligodendroglioma

Conference JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 10, 2024 Link to item Cite

Abstract 5496: Multi-omic spatial analysis of the tumor microenvironment in gliomas

Conference Cancer Research · March 22, 2024 AbstractIntroduction: The diverse tumor environment of high-grade glioma, which remains refractory to treatment, demands new innovative, multi-omic approaches to characterize tumor heterogeneity and expressi ... Full text Cite

LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION

Conference Neuro-Oncology · June 12, 2023 AbstractGangliogliomas are glioneuronal brain tumors that typically present in childhood or early adulthood. Though most often low-grade, new insights are needed to refine glioneuronal tumor classification a ... Full text Cite

Hepatocyte Smoothened Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver Disease.

Conference Cell Mol Gastroenterol Hepatol · 2023 BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis, strongly associates with the metabolic syndrome, an insulin-resistant proinflammatory state that disrupts energy balance and promotes progressive liver degeneration. We a ... Full text Link to item Cite

Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.

Conference Prostate Cancer Prostatic Dis · September 2022 BACKGROUND: Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficu ... Full text Open Access Link to item Cite

Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.

Conference Journal of Clinical Oncology · February 20, 2022 139 Background: Androgen receptor signaling inhibitors (ARSi) are a mainstay for patients with metastatic castration-resistant prostate cancer (mCRPC). However, patient response is heterogeneous and the molecular underpinnings of ... Full text Cite

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ... Full text Link to item Cite

Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.

Conference Mol Cancer Res · June 2021 Men with circulating tumor cell (CTC) AR-V7-positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive biomarkers ar ... Full text Link to item Cite

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.

Conference Journal of Clinical Oncology · February 20, 2018 160 Background: Radium-223 is a targeted alpha therapy that improves survival in men with mCRPC. The biologic basis for radium-223 efficacy is not completely understood. We hypothesized that PC osteomimicry, a form of epithelial ... Full text Cite

Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.

Conference Journal of Clinical Oncology · February 1, 2014 65 Background: Given the evolving treatments available in metastatic castration resistant prostate cancer (mCRPC), predictive biomarkers are desirable that maximize benefit and minimize harms and costs.The goal of this study was ... Full text Cite

An Investigation of Mitochondrial Haplogroups in Fuchs Endothelial Corneal Dystrophy

Conference INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · June 1, 2013 Link to item Cite

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

Conference Med Pediatr Oncol · January 2001 BACKGROUND: Chromosome 1p deletions are common in advanced neuroblastomas, but the biological and clinical implications of this clonal rearrangement remain controversial. Previous studies of chromosome 1p loss of heterozygosity (LOH) have been limited by a ... Full text Link to item Cite

Mapping and sequence analysis of human chromosome 1

Conference CYTOGENETICS AND CELL GENETICS · 1997 Link to item Cite